menu
    • menu

    Company profile for iVeena

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    iVeena Delivery Systems, Inc. (iVeena) is a privately held, clinical stage biopharmaceutical company focusing on expanding its platform technology for non-invasive, pharmacologic corneal flattening to develop products that address unmet medical needs in ophthalmology. The company’s lead program is IVMED-80, a novel treatment for keratoconus. iVeena is also developing IVMED-85 and IVMED-95 for the treatment of pediatric hi...
    iVeena Delivery Systems, Inc. (iVeena) is a privately held, clinical stage biopharmaceutical company focusing on expanding its platform technology for non-invasive, pharmacologic corneal flattening to develop products that address unmet medical needs in ophthalmology. The company’s lead program is IVMED-80, a novel treatment for keratoconus. iVeena is also developing IVMED-85 and IVMED-95 for the treatment of pediatric high myopia and adult low myopia respectively.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    iVeenaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    391 Chipeta Way, Suite I Salt Lake City, Utah, 84108
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://iveenamed.com/index.php
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    iVeena Gets $2M NEI Grant for Pediatric Myopia Therapy
    iVeena Gets $2M NEI Grant for Pediatric Myopia Therapy

    18 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250918460161/en/iVeena-Awarded-%242-Million-National-Eye-Institute-Grant-to-Advance-Novel-Therapy-for-Pediatric-Myopia

    BUSINESSWIRE
    18 Sep 2025
    Share Share
    iVeena submits IND for Pediatric Myopia Phase 2 Trial to FDA
    iVeena submits IND for Pediatric Myopia Phase 2 Trial to FDA

    29 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250529019084/en/iVeena-Announces-IND-Submission-to-the-U.S.-FDA-for-a-Phase-2-Clinical-Trial-for-Pediatric-Myopia

    BUSINESSWIRE
    29 May 2025
    Share Share
    iVeena Secures $3M in Series B-2 Financing for IVMED-85 in Myopia
    iVeena Secures $3M in Series B-2 Financing for IVMED-85 in Myopia

    05 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250205113508/en

    BUSINESSWIRE
    05 Feb 2025
    Share Share
    iVeena Awarded NEI-SBIR Grant For Progressive Myopia Drug Candidate IVMED-85
    iVeena Awarded NEI-SBIR Grant For Progressive Myopia Drug Candidate IVMED-85

    26 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231026066849/en

    BUSINESSWIRE
    26 Oct 2023
    Share Share
    Burns & Levinson Represents iVeena in Licensing Agreement with Glaukos Corp
    Burns & Levinson Represents iVeena in Licensing Agreement with Glaukos Corp

    29 Aug 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/burns--levinson-represents-iveena-delivery-systems-inc-in-strategic-licensing-agreement-with-glaukos-corporation-301614032.html

    PRNEWSWIRE
    29 Aug 2022
    Share Share
    Glaukos Corporation Announces Second Quarter 2022 Financial Results
    Glaukos Corporation Announces Second Quarter 2022 Financial Results

    03 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220803005379/en

    BUSINESSWIRE
    03 Aug 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search